Zhipu, Jiangmen, QuantGroup and Other Investors Join Forces to Back RMB 1 Billion Cognitive Intelligence Venture Capital Fund for Physical AI Ecosystem Development

Hong Kong, Oct 22, 2026 - (ACN Newswire via SeaPRwire.com) - Competition in AI has evolved from contests over individual technologies into a new phase defined by coordination across foundational ecosystems and industry value chains. Zhipu, a leading large-model developer, has again expanded its footprint as a limited partner (LP)…

WooshPay and AlphaToken, part of Yunfeng Financial Group (HKEX: 0376), sign strategic partnership agreement to advance AI payment technology and agentic payments

EQS via SeaPRwire.com / 22/10/2026 / 17:07 UTC+8 HONG KONG, 22 October 2026 — WooshPay, a global cross-border payments company, has signed a strategic partnership agreement with AlphaToken (AlphaToken Technology (HK) Limited), the digital finance infrastructure platform of Yunfeng Financial Group (HKEX: 0376). In line with applicable regulatory requirements, the…

Felix Cheung of Bairong-W (06608.HK) Addresses First Seafront Fund Strategy Summit: AI Roll-up Reshapes Industries as AICC Scaling Accelerates

EQS via SeaPRwire.com / 22/10/2026 / 10:13 UTC+8 Abstract: In his keynote speech, Felix Cheung systematically outlined the critical path for AI scaling from foundational models to enterprise-grade AI agents. He noted that AI had evolved beyond an assistant tool to a workforce component (AI agents). Enterprises are shifting from…

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027

Mountain View, CA, 21 Oct, 2026 - (ACN Newswire via SeaPRwire.com) - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug…

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027

Mountain View, CA, 21 Oct, 2026 - (ACN Newswire via SeaPRwire.com) - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug…